GSK’s Benlysta (belimumab) Receives the US FDA’s Approval for the Treatment of Active Lupus Nephritis in Pediatric Patients
Shots:
- The US FDA has approved Benlysta (BLyS-specific inhibitor) for the treatment of active LN who received standard therapy in children aged 5 to 17yrs.
- The main objective of treating lupus nephritis in both adults and children is to maintain renal function while reducing side effects from treatment and associated morbidity
- Benlysta is a human mAb that binds to soluble BLyS. The therapy has the potential to suppress B cell survival incl. autoreactive B cells and slows down the development of B cells into immunoglobulin-producing plasma cells by binding to BLyS
Ref: Businesswire | Image: GSK
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
